Screener
Cogent Biosciences, Inc. COGT Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:21 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205170
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 103,607 | 74,933 |
| Loss from operations | (103,607) | (74,933) |
| Other income: | ||
| Interest income | 7,608 | 2,952 |
| Interest expense | (1,213) | — |
| Other income (expense), net | (140) | (5) |
| Total other income, net | 6,255 | 2,947 |
| Net loss | $(97,352) | $(71,986) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Cogent Biosciences, Inc.'s interest income?
- Cogent Biosciences, Inc. (COGT) reported interest income of $7.61M in Q1 2026.
- How has Cogent Biosciences, Inc.'s interest income changed year-over-year?
- Cogent Biosciences, Inc.'s interest income increased by 157.7% year-over-year, from $2.95M to $7.61M.
- What is the long-term trend for Cogent Biosciences, Inc.'s interest income?
- Over 4 years (2021 to 2025), Cogent Biosciences, Inc.'s interest income has grown at a 136.8% compound annual growth rate (CAGR), from $467K to $14.69M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Cogent Biosciences, Inc.'s interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude